Recruitment

Recruitment Status
Withdrawn
Estimated Enrollment
10000

Inclusion Criterias

Willing to give informed consent for participating in this study
Patient will be enrolled after the decision to administer acarbose/metformin fixed dose combination for type-2 diabetes management has been made by the attending physician on the basis of best clinical practice and patient needs.
Willing to give informed consent for participating in this study
Patient will be enrolled after the decision to administer acarbose/metformin fixed dose combination for type-2 diabetes management has been made by the attending physician on the basis of best clinical practice and patient needs.

Exclusion Criterias

Exclusion criteria should be read in conjunction with local product information
Patients receiving anti-diabetic medication other than acarbose, or metformin monotherapy at the time of enrollment in the study will be excluded. However, during observation period, any additional anti-diabetics medication administered by the attending physician will be allowed & recorded in case record form.
Patient receiving acarbose/metformin fixed dose combination during 3-months prior to enrollment.
Exclusion criteria should be read in conjunction with local product information
Patients receiving anti-diabetic medication other than acarbose, or metformin monotherapy at the time of enrollment in the study will be excluded. However, during observation period, any additional anti-diabetics medication administered by the attending physician will be allowed & recorded in case record form.
Patient receiving acarbose/metformin fixed dose combination during 3-months prior to enrollment.

Summary

Conditions
Diabetes Mellitus, Type 2
Type
Observational
Design
  • Observational Model: Cohort
  • Time Perspective: Prospective

Participation Requirements

Age
Younger than 125 years
Gender
Both males and females

Inclusion Criterias

Willing to give informed consent for participating in this study
Patient will be enrolled after the decision to administer acarbose/metformin fixed dose combination for type-2 diabetes management has been made by the attending physician on the basis of best clinical practice and patient needs.
Willing to give informed consent for participating in this study
Patient will be enrolled after the decision to administer acarbose/metformin fixed dose combination for type-2 diabetes management has been made by the attending physician on the basis of best clinical practice and patient needs.

Exclusion Criterias

Exclusion criteria should be read in conjunction with local product information
Patients receiving anti-diabetic medication other than acarbose, or metformin monotherapy at the time of enrollment in the study will be excluded. However, during observation period, any additional anti-diabetics medication administered by the attending physician will be allowed & recorded in case record form.
Patient receiving acarbose/metformin fixed dose combination during 3-months prior to enrollment.
Exclusion criteria should be read in conjunction with local product information
Patients receiving anti-diabetic medication other than acarbose, or metformin monotherapy at the time of enrollment in the study will be excluded. However, during observation period, any additional anti-diabetics medication administered by the attending physician will be allowed & recorded in case record form.
Patient receiving acarbose/metformin fixed dose combination during 3-months prior to enrollment.

Tracking Information

NCT #
NCT01915264
Collaborators
Not Provided
Investigators
Study Director: Bayer Study Director Bayer